Jared Gollob
Vermogen: 6 M $ op 31-05-2026
Vermogen: 6 M $ op 31-05-2026
Dr. Jared Gollob, MD, is a Chief Medical Officer at Kymera Therapeutics, Inc. Dr. Gollob was previously employed as a Global VP-Medical Affairs & Clinical Development by Alnylam Pharmaceuticals, Inc. and a Director-Biologic Therapy Program by Duke University.
He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from The Trustees of Columbia University in The City of New York.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 71.359 ( 0,09% ) | 6 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2018 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-08-2018 |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01-09-2007 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau